autologous myelin peptide-coupled cells

Autologous myelin peptide-coupled cells is an investigational cell therapy designed to induce antigen-specific immune tolerance in patients with multiple sclerosis (MS). The approach involves isolating a patient's own peripheral blood mononuclear cells (PBMCs), chemically coupling them with a panel of seven immunodominant peptides derived from major myelin proteins—myelin oligodendrocyte glycoprotein (MOG1-20, MOG35-55), myelin basic protein (MBP13-32, MBP83-99, MBP111-129, MBP146-170), and proteolipid protein (PLP139-154)—using the crosslinker EDC. These modified autologous PBMCs are then reinfused into the patient. The mechanism of action is based on inducing peripheral immune tolerance by presenting these self-antigens in a non-inflammatory context to T lymphocytes, thereby reducing pathogenic autoreactive T cell responses against central nervous system antigens implicated in MS. Early-phase clinical trials have demonstrated feasibility and safety in both relapsing-remitting and secondary progressive MS patients who exhibit T cell reactivity to at least one of the included peptides. Higher doses were associated with decreased antigen-specific T cell responses post-treatment[1][2][3][6].

Brand names

ETIMS

Other names

antigen-coupled cell therapyETIMSautologous peptide-coupled cellsmyelin-peptide coupled red blood cells